Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to provide its Quarterly Business Update to the market.
Highlights
Revenues from customers of A$99k in the quarter (unaudited), up from A$6k in Q3, including receipt of first month IBX sales
Confirmed launch of COVID-19 Risk Test by Infinity Biologix in the US
Confirmed grant of US Patent No 11,031,098 - ‘Computer Systems and Methods for Genomic Analysis’ (ASX Announcement on 11 June 2021)
Post quarter end acquisition of EasyDNA for US$4 million; strategically, this direct-to-consumer acquisition provides the foundation to grow the portfolio of serious disease tests across well-established websites in 40 countries
Strong cash balance of A$20.8 million as at 30 June 2021 provides runway to fund commercialization opportunities and continued product development
Net cash used for operations of A$2.12 million, an increase on the prior quarter (Q3 FY21: A$1.08 million) due mainly to the increase in R&D and operating expense of A$353k and receipt in Q3 of the R&D tax incentive receipt for A$763k
Appointment of Carl Stubbings as Chief Commercial Officer and commencement of Mike Tonroe as Chief Financial Officer
Simon Morriss, CEO of Genetic Technologies, stated, “Genetic Technologies is moving rapidly into the commercialization of its products with the launch of its COVID-19 Risk Test in May and the post quarter end announcement of the acquisition of EasyDNA.”
“This acquisition provides a direct-to-consumer platform and strong alignment with GTG’s planned expansion into health and wellness testing across well-established websites in 40 countries. This alignment was critical to our decision to acquire the brand and assets of EasyDNA,” continued Morriss.
Commercialization Update
Launch of COVID-19 Serious Disease Risk Test
The three-year co-exclusive licence agreement between IBX and GTG was announced on 3 March 2021 for the production, distribution, sales and marketing of GTG’s COVID-19 Risk Test in the US with the product launch at the end of May 2021. Revenues in the quarter from the IBX agreement were A$95k.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.